Search Results - "Gladden, Allison"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy

    Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy by Petrylak, Daniel Peter, Tagawa, Scott T., Jain, Rohit K., Bupathi, Manojkumar, Balar, Arjun Vasant, Rezazadeh, Arash, George, Saby, Palmbos, Phillip Lee, Nordquist, Luke T., Davis, Nancy B., Vogelzang, Nicholas J., Ramamurthy, Chethan, Sternberg, Cora N., Loriot, Yohann, Agarwal, Neeraj, Hong, Quan, Gladden, Allison, Kanwal, Charu, Goswami, Trishna, Grivas, Petros

    Published in Journal of clinical oncology (20-05-2020)
    “…Abstract only 5027 Background: SG is an antibody-drug conjugate consisting of a humanized monoclonal anti–Trop-2 antibody coupled to the cytotoxic agent,…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT

    A randomized, open-label study to compare the efficacy and safety of AT1001 and enzyme replacement therapy (ERT) in patients with Fabry disease and AT1001-responsive GLA mutations, who were previously treated with ERT by Adera, Mathews, Gladden, Allison, Boudes, Pol

    Published in Molecular genetics and metabolism (01-02-2011)
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: